Urgent.News

What's breaking now, across hundreds of outlets.

Health & Medicine

High GPX4 Expression Marks an Oxidative-Metabolic, PD-L1/CD47-Low and Stroma-Poor Tumor State in Hepatocellular Carcinoma

Background: Glutathione peroxidase 4 (GPX4) protects cancer cells from ferroptosis and is a candidate therapeutic target in hepatocellular carcinoma (HCC). How GPX4 expression relates to the immune and metabolic features of patient tumors is not well characterized. Methods: We analyzed RNA-sequencing data from 366 primary tumors of the TCGA-LIHC PanCancer Atlas cohort (365 with survival data).…

A study has found that increased expression of a protein called Glutathione peroxidase 4 (GPX4) in hepatocellular carcinoma (HCC) tumors is linked to a specific set of immune and metabolic characteristics. The research, which analyzed RNA-sequencing data from 366 primary HCC tumors, discovered that tumors with higher GPX4 expression tend to have lower levels of PD-L1, CD47, CD163, and a fibroblast/extracellular-matrix score.

These associations remained significant even after adjusting for factors such as tumor purity, CTNNB1 and TP53 mutations, age, and sex.

The study further revealed that GPX4-high tumors exhibit enrichment in oxidative phosphorylation, mitochondrial, fatty-acid, xenobiotic, and glutathione metabolism programs, while they lack extracellular-matrix, TGF-beta, and cell-adhesion programs. However, GPX4 expression did not correlate with a T-cell-inflamed profile, CD8 T-cell score, cytolytic activity, or an NRF2 target-gene score.

In fact, higher GPX4 expression was associated with lower expression of NFE2L2. Despite the findings, the research indicates that GPX4 expression does not have a prognostic value in HCC patients, as it does not impact overall survival. The study's correlative findings are based on a single cohort and require further external validation and functional testing.

Rewritten by urgent.news; may contain errors — check the original.

Source: biorxiv.org

Read the original at biorxiv.org →

Report a problem with this story

More in Health & Medicine

More from Sunday 22 November →